Deep vein thrombosis landmark trials in treatment

Ventricular tachycardia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ventricular Tachycardia from other Disorders
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography
Cardiac MRI
Other Diagnostic Tests
Treatment
Medical Therapy
Electrical Cardioversion
Ablation
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Deep vein thrombosis landmark trials in treatment On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Deep vein thrombosis landmark trials in treatment
CDC onDeep vein thrombosis landmark trials in treatment
Deep vein thrombosis landmark trials in treatment in the news
Blogs on Deep vein thrombosis landmark trials in treatment
to Hospitals Treating Deep vein thrombosis landmark trials in treatment
Risk calculators and risk factors for Deep vein thrombosis landmark trials in treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-in Chief: Avirup Guha, M.B.B.S.[2]

Landmark Clinical Trials

Studies of secondary prevention of sudden cardiac death

1. AVID (The Antiarrhythmics versus Implantable Defibrillators)

• Strategy: ICD vs medication either amiodarone or sotalol

• Demographics: Total: 1016 ICD: 507 Medications (predominantly amiodarone): 509 (80% with ischemic heart disease)

• Mean EF: 32 (inclusion<40)

• Result: Relative risk reduction: 1-year: 39% ; 2-year: 27% ; 3-year: 31% (p = 0.02)